These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 10616906

  • 1. A genetic analysis of PAX3-FKHR, the oncogene of alveolar rhabdomyosarcoma.
    Kempf BE, Vogt PK.
    Cell Growth Differ; 1999 Dec; 10(12):813-8. PubMed ID: 10616906
    [Abstract] [Full Text] [Related]

  • 2. Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains.
    Bennicelli JL, Fredericks WJ, Wilson RB, Rauscher FJ, Barr FG.
    Oncogene; 1995 Jul 06; 11(1):119-30. PubMed ID: 7624119
    [Abstract] [Full Text] [Related]

  • 3. The alveolar rhabdomyosarcoma PAX3/FKHR fusion protein is a transcriptional activator.
    Sublett JE, Jeon IS, Shapiro DN.
    Oncogene; 1995 Aug 03; 11(3):545-52. PubMed ID: 7630639
    [Abstract] [Full Text] [Related]

  • 4. The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture.
    Scheidler S, Fredericks WJ, Rauscher FJ, Barr FG, Vogt PK.
    Proc Natl Acad Sci U S A; 1996 Sep 03; 93(18):9805-9. PubMed ID: 8790412
    [Abstract] [Full Text] [Related]

  • 5. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma.
    Barr FG.
    Oncogene; 2001 Sep 10; 20(40):5736-46. PubMed ID: 11607823
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma.
    Bennicelli JL, Edwards RH, Barr FG.
    Proc Natl Acad Sci U S A; 1996 May 28; 93(11):5455-9. PubMed ID: 8643596
    [Abstract] [Full Text] [Related]

  • 8. The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain.
    Lam PY, Sublett JE, Hollenbach AD, Roussel MF.
    Mol Cell Biol; 1999 Jan 28; 19(1):594-601. PubMed ID: 9858583
    [Abstract] [Full Text] [Related]

  • 9. Analysis of the transforming and growth suppressive activities of the PAX3-FKHR oncoprotein.
    Xia SJ, Barr FG.
    Oncogene; 2004 Sep 09; 23(41):6864-71. PubMed ID: 15286710
    [Abstract] [Full Text] [Related]

  • 10. Hormone-dependent tumor regression in vivo by an inducible transcriptional repressor directed at the PAX3-FKHR oncogene.
    Ayyanathan K, Fredericks WJ, Berking C, Herlyn M, Balakrishnan C, Gunther E, Rauscher FJ.
    Cancer Res; 2000 Oct 15; 60(20):5803-14. PubMed ID: 11059777
    [Abstract] [Full Text] [Related]

  • 11. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3.
    Fredericks WJ, Galili N, Mukhopadhyay S, Rovera G, Bennicelli J, Barr FG, Rauscher FJ.
    Mol Cell Biol; 1995 Mar 15; 15(3):1522-35. PubMed ID: 7862145
    [Abstract] [Full Text] [Related]

  • 12. PAX3/forkhead homolog in rhabdomyosarcoma oncoprotein activates glucose transporter 4 gene expression in vivo and in vitro.
    Armoni M, Quon MJ, Maor G, Avigad S, Shapiro DN, Harel C, Esposito D, Goshen Y, Yaniv I, Karnieli E.
    J Clin Endocrinol Metab; 2002 Nov 15; 87(11):5312-24. PubMed ID: 12414908
    [Abstract] [Full Text] [Related]

  • 13. Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome?
    Anderson J, Gordon T, McManus A, Mapp T, Gould S, Kelsey A, McDowell H, Pinkerton R, Shipley J, Pritchard-Jones K, UK Children's Cancer Study Group (UKCCSG) and the UK Cancer Cytogenetics Group.
    Br J Cancer; 2001 Sep 14; 85(6):831-5. PubMed ID: 11556833
    [Abstract] [Full Text] [Related]

  • 14. Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions.
    Barr FG, Qualman SJ, Macris MH, Melnyk N, Lawlor ER, Strzelecki DM, Triche TJ, Bridge JA, Sorensen PH.
    Cancer Res; 2002 Aug 15; 62(16):4704-10. PubMed ID: 12183429
    [Abstract] [Full Text] [Related]

  • 15. PAX3-FKHR transformation increases 26 S proteasome-dependent degradation of p27Kip1, a potential role for elevated Skp2 expression.
    Zhang L, Wang C.
    J Biol Chem; 2003 Jan 03; 278(1):27-36. PubMed ID: 12401804
    [Abstract] [Full Text] [Related]

  • 16. PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma.
    Bennicelli JL, Advani S, Schäfer BW, Barr FG.
    Oncogene; 1999 Jul 29; 18(30):4348-56. PubMed ID: 10439042
    [Abstract] [Full Text] [Related]

  • 17. Lack of effective T-lymphocyte response to the PAX3/FKHR translocation area in alveolar rhabdomyosarcoma.
    Rodeberg DA, Nuss RA, Heppelmann CJ, Celis E.
    Cancer Immunol Immunother; 2005 Jun 29; 54(6):526-34. PubMed ID: 15838707
    [Abstract] [Full Text] [Related]

  • 18. Tumor-specific PAX3-FKHR transcription factor, but not PAX3, activates the platelet-derived growth factor alpha receptor.
    Epstein JA, Song B, Lakkis M, Wang C.
    Mol Cell Biol; 1998 Jul 29; 18(7):4118-30. PubMed ID: 9632796
    [Abstract] [Full Text] [Related]

  • 19. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.
    Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ, Barr FG.
    J Clin Oncol; 2002 Jun 01; 20(11):2672-9. PubMed ID: 12039929
    [Abstract] [Full Text] [Related]

  • 20. The Pax3-FKHR oncoprotein is unresponsive to the Pax3-associated repressor hDaxx.
    Hollenbach AD, Sublett JE, McPherson CJ, Grosveld G.
    EMBO J; 1999 Jul 01; 18(13):3702-11. PubMed ID: 10393185
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.